Business
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
Jaguar is also supporting a third-party investigator evaluating crofelemer for eosinophilic colitis, another rare pediatric gastrointestinal
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Jaguar is also supporting a third-party investigator evaluating crofelemer for eosinophilic colitis, another rare pediatric gastrointestinal conditionProof-of-concept data for the use of crofelemer for pediatric orphan or rare disorders is expected to provide additional support for the potential for expanded patient access to crofelemer through programs in Europe in late 2023SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Therapeutics, the corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access for orphan and rare diseases in Europe, today announced that an update regarding a third-party clinical investigation of crofelemer for pediatric short bowel syndrome (SBS) and congenital diarrheal disorders (CCD) was presented at the World Congress of Gastroenterology, a global GI conference that took place December 12-14, 2023 in Dubai in the United Arab Emirates (UAE). This update was provided by the clinical investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City in the UAE.Dr. Miqdady is also expected to make a presentation about this trial in May 2023 at the Annual Elite Ped-GI Congress in Abu Dhabi in the UAE.\"The update at the Annual Elite Ped-GI Congress is part of a series of planned presentations in the first half of 2023 on investigator-initiated proof-of-concept clinical studies of crofelemer for pediatric gastrointestinal orphan or rare diseases which remain a significant unmet medical need,\" said Lisa Conte, Jaguar's president and CEO. \"Clinical studies of crofelemer for addressing pediatric SBS and CDD conditions are expected to be conducted throughout 2023. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support early patient access of crofelemer for pediatric SBS or CDD, especially for patients with intestinal failure requiring parenteral support, by late 2023 through programs in Europe for these debilitating conditions. Participation in Early Access Programs in some EU countries provides an opportunity for reimbursement while impacting the morbidity and high cost of care for these chronic unmet needs. SBS affects approximately 10,000 to 20,000 people in the EU and similar pre...